Effect of medroxyprogesterone acetate on the efficiency of an oral protein-rich nutritional support in HIV-infected patients

Céécile Rochon; Magali Prod'Homme; Henri Laurichesse; Igor Tauveron; Michèle Balage; Florence Gourdon; Olivier Baud; Christine Jacomet; Sylvie Jouvency; Gérard Bayle; Claude Champredon; Philippe Thieblot; Jean Beytout; Jean Grizard

doi:doi:10.1051/rnd:2003017

All issues

Volume 43 / No 2 (March-April 2003)

Reprod. Nutr. Dev., 43 2 (2003) 203-214

Abstract

Free Access

Issue		Reprod. Nutr. Dev. Volume 43, Number 2, March-April 2003


Page(s)		203 - 214
DOI		https://doi.org/10.1051/rnd:2003017

Reprod. Nutr. Dev. 43 (2003) 203-214
DOI: 10.1051/rnd:2003017

Effect of medroxyprogesterone acetate on the efficiency of an oral protein-rich nutritional support in HIV-infected patients

Céécile Rochon^a, Magali Prod'Homme^a, Henri Laurichesse^b, Igor Tauveron^c, Michèle Balage^a, Florence Gourdon^b, Olivier Baud^b, Christine Jacomet^b, Sylvie Jouvency^b, Gérard Bayle^a, Claude Champredon^a, Philippe Thieblot^c, Jean Beytout^b and Jean Grizard^a

^a Unité de Nutrition et Métabolisme Protéique, INRA, Centre de Clermont-Ferrand-Theix, 63122 Saint-Genès-Champanelle, France
^b Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire, 63003 Clermont-Ferrand, France
^c Service d'Endocrinologie et Maladies Métaboliques, Centre Hospitalier Universitaire, Centre de Recherche en Nutrition Humaine, 63003 Clermont-Ferrand, France

(Received 24 July 2002; accepted 10 April 2003)

Abstract
We have examined the effect of a medroxyprogesterone therapy in HIV-infected patients under appropriate nutrition for anabolism. The experiments were performed on 12 men (mean age 40 y), HIV seropositive but free of any clinically active opportunistic infection for at least one month. The patients underwent a 2-week baseline diet period (1.2 g protein $\cdot$ kg ^-1 body weight (BW) $\cdot$ d ^-1) and then a 5-week experimental period with again the baseline diet in conjunction with supplements including Tonexis HP (0.7 g protein $\cdot$ kg ^-1 BW) $\cdot$ d ^-1), L-threonine (0.018 g $\cdot$ kg ^-1 BW $\cdot$ d ^-1) and L-methionine (0.013 g $\cdot$ kg ^-1 BW $\cdot$ d ^-1). Indeed HIV-infected patients showed deficiencies in these amino acids. They were randomly divided into groups I and II under double- blinded condition. Group II was given medroxyprogesterone acetate (0.4 g $\cdot$ d ^-1) during the last 3 weeks whereas group I received a placebo. All the patients significantly increased their body weight ( P < 0.05) during the experimental periods. Those under medroxyprogesterone tended to show a higher but not significant weight gain (+3.1 $\pm$ 1.0 kg in group II and +1.9 $\pm$ 0.3 kg in group I). Blood free amino acids were used as rough indicators of amino acid utilization and were analyzed prior and during acute 150 min intravenous infusion of a complete glucose-amino acid mixture. This test was done before and at the end of the experimental periods. Basal essential blood free amino acids were similar in the two groups and did not change during the experimental period. Most essential amino acids increased following glucose-amino acid infusions. The incremental increase was of less magnitude after the experimental period than before when medroxyprogesterone was present ( P < 0.05 for valine, leucine, lysine, threonine and methionine). This was not the case in the absence of the hormone. We concluded that medroxyprogesterone might improve the efficacy of an oral protein-rich nutritional support in HIV-infected patients.

Key words: body weight / amino acid / hormonal therapy / AIDS

Correspondence and reprints: Michèle Balage email: balage@clermont.inra.fr

© INRA, EDP Sciences 2003